Factor VIII Antibody (R8B12): sc-73597

Factor VIII Antibody (R8B12) is a mouse monoclonal IgG1 kappa light chain antibody designed to recognize the A2 domain of human Factor VIII. Factor VIII, also known as Factor 8, F8, coagulation factor VIII, or FVIII, is a complex glycoprotein composed of multiple domains (A1, A2, B, A3, C1, and C2) that play crucial roles in the blood coagulation cascade, specifically in the intrinsic pathway where it acts as a cofactor for Factor IXa in the activation of Factor X to Factor Xa. The intricate structure of Factor VIII, including its heavy and light chains, is essential for stability, interaction with other coagulation factors, and binding to von Willebrand factor (VWF), which protects from rapid degradation in the bloodstream. The A2 domain, targeted by Factor VIII (R8B12) monoclonal antibody, is pivotal for Factor VIII′s interaction with Factor IXa, and any structural alterations in this domain can impair function, leading to hemophilia A, a severe hereditary bleeding disorder. Anti-Factor VIII antibody (R8B12) effectively detects Factor VIII from mouse, rat, and human origins through western blotting (WB) and immunoprecipitation (IP), demonstrating broad utility in various research applications. By specifically binding to the A2 domain, Factor VIII (R8B12) antibody facilitates detailed studies on structural integrity and functional dynamics of Factor VIII, enabling researchers to elucidate molecular mechanisms underlying coagulation and the impact of mutations that cause hemophilia A. Additionally, understanding Factor VIII′s structure through Factor VIII monoclonal antibody (R8B12) aids in developing targeted therapies and improving diagnostic assays, ultimately contributing to better management and treatment of coagulation disorders. Overall, anti-Factor VIII antibody (R8B12) provides researchers and clinicians with a robust means to investigate essential structural and functional aspects of Factor VIII, advancing the understanding and treatment of critical coagulation disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Factor VIII Antibody (R8B12) References:

1. Blood coagulation factor VIII: An overview.  |  Bhopale, GM. and Nanda, RK. 2003. J Biosci. 28: 783-9. PMID: 14660878
2. Mutating factor VIII: lessons from structure to function.  |  Fay, PJ. and Jenkins, PV. 2005. Blood Rev. 19: 15-27. PMID: 15572214
3. Biological regulation of factor VIII activity.  |  Kaufman, RJ. 1992. Annu Rev Med. 43: 325-39. PMID: 1580593
4. Factor VIII structure and function.  |  Foster, PA. and Zimmerman, TS. 1989. Blood Rev. 3: 180-91. PMID: 2506958
5. The factor VIII protein and its function.  |  Mazurkiewicz-Pisarek, A., et al. 2016. Acta Biochim Pol. 63: 11-16. PMID: 26824291
6. The evolving understanding of factor VIII binding sites and implications for the treatment of hemophilia A.  |  Gilbert, GE. 2019. Blood Rev. 33: 1-5. PMID: 29866493
7. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.  |  Eaton, D., et al. 1986. Biochemistry. 25: 505-12. PMID: 3082357
8. Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Insights from Pivotal and Extension Studies.  |  Di Minno, MND., et al. 2021. Semin Thromb Hemost. 47: 32-42. PMID: 33348412
9. Induction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors.  |  Young, G. 2024. Blood Adv.. PMID: 39418639
10. Thrombin proteolysis of purified factor viii procoagulant protein: correlation of activation with generation of a specific polypeptide.  |  Fulcher, CA., et al. 1983. Blood. 61: 807-11. PMID: 6403080
11. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.  |  Saenko, EL. and Scandella, D. 1997. J Biol Chem. 272: 18007-14. PMID: 9218428
12. Factor VIII inhibitors in mild and moderate-severity haemophilia A.  |  Hay, CR. 1998. Haemophilia. 4: 558-63. PMID: 9873794

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Factor VIII Antibody (R8B12) has 6 citations in a variety of scientific publications.

Primary antibodies like Anti-Factor VIII Antibody (R8B12) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Factor VIII Antibody (R8B12) Specifications

Alternate Product Name: Factor VIII

Product Clone Name: R8B12

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: Factor VIII

Epitope Species: human

Product Reactivity/Detection: Factor VIII

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 6 citations in various scientific publications

Available Conjugates/Forms for Factor VIII Antibody (R8B12): N/A